GlaxoSmithKline plc (GSK) announced that Robert A. Ingram, currently Chief Operating Officer and President, Pharmaceutical Operations, will retire from that position effective 31st December 2002. He will continue to work part-time as Vice-Chairman of Pharmaceuticals, acting as a special advisor to the Group and representing GSK on the board of the US Pharmaceutical Research and Manufacturers' Association (PhRMA). David Stout, currently President, US Pharmaceuticals, will be named President, Pharmaceuticals Operations and will report to Jean-Pierre Garnier, Chief Executive Officer.

Stout will be responsible for management of the Group's global pharmaceuticals business, and will be based at GSK's offices in Philadelphia, PA. David Stout will be succeeded as President, US Pharmaceuticals by Chris Viehbacher, currently President, Pharmaceuticals, Europe. Chris Viehbacher will be based at GSK's offices in Research Triangle Park. Andrew Witty, currently Senior Vice President, Asia Pacific, will succeed Chris Viehbacher as President, Pharmaceuticals, Europe. He will be based at the company's corporate headquarters in London. Chris Viehbacher and Andrew Witty will report to David Stout.

Jean-Pierre Garnier said: "Bob Ingram is a true statesman and an unrivalled ambassador for both GSK and the pharmaceutical industry. He is admired as a role model and leader within GSK, and is recognised as an outstanding representative of both our company and our industry by the people he works with outside GSK. We are delighted that Bob will continue to use his considerable talents on behalf of our company as Vice Chairman of Pharmaceuticals. I would like to personally thank Bob - and pass along the thanks and best wishes of all our employees - for his many contributions to GSK, in particular his strong leadership, wisdom and guidance throughout the integration process".

Bob Ingram said: "I have immensely enjoyed the many years I have worked in an industry that makes such a difference in improving the lives and health of so many people throughout the world. In particular, I have always considered it an honour to work with GSK's management team and employees, all of whom exhibit such a high quality of professionalism, expertise and dedication. These are very special people, working at a very special company, in a very special industry. For that reason, I am very proud to have the opportunity to continue working on behalf of GSK."